RATIONALE: The mechanism by which viruses cause exacerbations of chronic airway disease and the capacity of patients with cystic fibrosis (CF) to respond to viral infection are not precisely known. OBJECTIVES: To determine the antiviral response to infection in patients with CF. METHODS: Sputum was collected from patients with CF with respiratory exacerbation. Viruses were detected in multiplex polymerase chain reaction (PCR)-based assays. Gene expression of 84 antiviral response genes was measured, using a focused quantitative PCR gene array. MEASUREMENTS AND MAIN RESULTS: We examined 36 samples from 23 patients with respiratory exacerbation. Fourteen samples tested virus-positive and 22 virus-negative. When we compared exacerbations associated with rhinovirus (RV, n = 9) and influenza (n = 5) with virus-negative specimens, we found distinct patterns of antiviral gene expression. RV was associated with greater than twofold induction of five genes, including those encoding the monocyte-attracting chemokines CXCL10, CXCL11, and CXCL9. Influenza was associated with overexpression of 20 genes, including those encoding the cytokines tumor necrosis factor and IL-12; the kinases MEK, TBK-1, and STAT-1; the apoptosis proteins caspase-8 and caspase-10; the influenza double-stranded RNA receptor RIG-I and its downstream effector MAVS; and pyrin, an IFN-stimulated protein involved in influenza resistance. CONCLUSIONS: We conclude that virus-induced exacerbations of CF are associated with immune responses tailored to specific infections. Influenza induced a more potent response consisting of inflammation, whereas RV infection had a pronounced effect on chemokine expression. As far as we are aware, this study is the first to compare specific responses to different viruses in live patients with chronic airway disease.
RATIONALE: The mechanism by which viruses cause exacerbations of chronic airway disease and the capacity of patients with cystic fibrosis (CF) to respond to viral infection are not precisely known. OBJECTIVES: To determine the antiviral response to infection in patients with CF. METHODS: Sputum was collected from patients with CF with respiratory exacerbation. Viruses were detected in multiplex polymerase chain reaction (PCR)-based assays. Gene expression of 84 antiviral response genes was measured, using a focused quantitative PCR gene array. MEASUREMENTS AND MAIN RESULTS: We examined 36 samples from 23 patients with respiratory exacerbation. Fourteen samples tested virus-positive and 22 virus-negative. When we compared exacerbations associated with rhinovirus (RV, n = 9) and influenza (n = 5) with virus-negative specimens, we found distinct patterns of antiviral gene expression. RV was associated with greater than twofold induction of five genes, including those encoding the monocyte-attracting chemokines CXCL10, CXCL11, and CXCL9. Influenza was associated with overexpression of 20 genes, including those encoding the cytokines tumor necrosis factor and IL-12; the kinases MEK, TBK-1, and STAT-1; the apoptosis proteins caspase-8 and caspase-10; the influenza double-stranded RNA receptor RIG-I and its downstream effector MAVS; and pyrin, an IFN-stimulated protein involved in influenza resistance. CONCLUSIONS: We conclude that virus-induced exacerbations of CF are associated with immune responses tailored to specific infections. Influenza induced a more potent response consisting of inflammation, whereas RV infection had a pronounced effect on chemokine expression. As far as we are aware, this study is the first to compare specific responses to different viruses in live patients with chronic airway disease.
Authors: J Collinson; K G Nicholson; E Cancio; J Ashman; D C Ireland; V Hammersley; J Kent; C O'Callaghan Journal: Thorax Date: 1996-11 Impact factor: 9.139
Authors: J Kelley Bentley; Uma S Sajjan; Marta B Dzaman; Nizar N Jarjour; Wai-Ming Lee; James E Gern; Marc B Hershenson Journal: J Allergy Clin Immunol Date: 2013-05-31 Impact factor: 10.793
Authors: Elisabeth Kieninger; Florian Singer; Caroline Tapparel; Marco P Alves; Philipp Latzin; Hui-Leng Tan; Cara Bossley; Carmen Casaulta; Andrew Bush; Jane C Davies; Laurent Kaiser; Nicolas Regamey Journal: Chest Date: 2013-03 Impact factor: 9.410
Authors: T C Lewis; T A Henderson; A R Carpenter; I A Ramirez; C L McHenry; A M Goldsmith; X Ren; G B Mentz; B Mukherjee; T G Robins; T A Joiner; L S Mohammad; E R Nguyen; M A Burns; D T Burke; M B Hershenson Journal: Clin Exp Allergy Date: 2012-12 Impact factor: 5.018
Authors: Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes Journal: Respir Med Date: 2021-11-23 Impact factor: 3.415
Authors: Elizabeth A Hines; Renee J Szakaly; Ning Leng; Anais T Webster; Jamie M Verheyden; Amber J Lashua; Christina Kendziorski; Louis A Rosenthal; James E Gern; Ronald L Sorkness; Xin Sun; Robert F Lemanske Journal: PLoS One Date: 2014-12-01 Impact factor: 3.240
Authors: Annika Luukkainen; Kia Joo Puan; Nurhashikin Yusof; Bernett Lee; Kai Sen Tan; Jing Liu; Yan Yan; Sanna Toppila-Salmi; Risto Renkonen; Vincent T Chow; Olaf Rotzschke; De Yun Wang Journal: Front Immunol Date: 2018-11-08 Impact factor: 7.561
Authors: Hanaa Banjar; Mohammad Chaballout; Kawthar Karkour; Hadeel Al-Ghamdi; Ibrahim Al-Mogarri; Sami Al-Haider; Imran Nizami; Rawia Raja; Ali AlNakhli Journal: Int J Pediatr Adolesc Med Date: 2019-09-12
Authors: Aline Schögler; Andrea B Stokes; Carmen Casaulta; Nicolas Regamey; Michael R Edwards; Sebastian L Johnston; Andreas Jung; Alexander Moeller; Thomas Geiser; Marco P Alves Journal: J Cyst Fibros Date: 2015-11-21 Impact factor: 5.482